
### [MONDO:0019141](http://purl.obolibrary.org/obo/MONDO_0019141)
**Label:** porokeratosis of mibelli

**Subclasses:** [MONDO:0008293](http://purl.obolibrary.org/obo/MONDO_0008293) (porokeratosis 3, disseminated superficial actinic type), [MONDO:0008290](http://purl.obolibrary.org/obo/MONDO_0008290) (POROK1), 

**Corr. equiv. classes:** [OMIM:175900](http://purl.obolibrary.org/obo/OMIM_175900), [OMIM:175800](http://purl.obolibrary.org/obo/OMIM_175800), 

**Class expressions from DL-Learner:**

- [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0011017](http://purl.obolibrary.org/obo/HP_0011017) (Abnormality of cell physiology) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0008404](http://purl.obolibrary.org/obo/HP_0008404) (Nail dystrophy) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0003674](http://purl.obolibrary.org/obo/HP_0003674) (Onset) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0003596](http://purl.obolibrary.org/obo/HP_0003596) (Middle age onset) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0003596](http://purl.obolibrary.org/obo/HP_0003596) (Middle age onset) and [HP:0011368](http://purl.obolibrary.org/obo/HP_0011368) (Epidermal thickening) 75.00%
- [HP:0003596](http://purl.obolibrary.org/obo/HP_0003596) (Middle age onset) and [HP:0011017](http://purl.obolibrary.org/obo/HP_0011017) (Abnormality of cell physiology) 75.00%
- [HP:0003581](http://purl.obolibrary.org/obo/HP_0003581) (Adult onset) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0003220](http://purl.obolibrary.org/obo/HP_0003220) (Abnormality of chromosome stability) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0003220](http://purl.obolibrary.org/obo/HP_0003220) (Abnormality of chromosome stability) and [HP:0003596](http://purl.obolibrary.org/obo/HP_0003596) (Middle age onset) 75.00%
- [HP:0001939](http://purl.obolibrary.org/obo/HP_0001939) (Abnormality of metabolism/homeostasis) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0001072](http://purl.obolibrary.org/obo/HP_0001072) (Thickened skin) and [HP:0003596](http://purl.obolibrary.org/obo/HP_0003596) (Middle age onset) 75.00%
- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0011017](http://purl.obolibrary.org/obo/HP_0011017) (Abnormality of cell physiology) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%
- [HP:0008069](http://purl.obolibrary.org/obo/HP_0008069) (Neoplasm of the skin) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) and [HP:0200044](http://purl.obolibrary.org/obo/HP_0200044) (Porokeratosis) 75.00%


